Omada Health pulled off something that was, especially at the time, highly unusual in the ever-burgeoning yet still-fledgling digital health space: In 2016, the company scored federal government reimbursements for its diabetes prevention program. It’s continued to grow since then and shared results from nine different peer-reviewed studies noting significant results for diabetes, cardiovascular disease, and obesity patients—a case study in how at least one company in the sphere is using data to try and fuel real world patient outcomes.
“It’s not about the data itself, it’s how you use it,” Omada co-founder and CEO Sean Duffy told Fortune in an interview earlier this year, echoing many of the chief executives and industry observers we spoke with for our recent feature on big data and AI in medicine. “The types of data that are going to be most useful going forward is the ‘in between’ data—what happens between actual health care visits,” he adds.
Read More: http://fortune.com/2018/04/17/diabetes-big-data-omada-health/
Via: Fortune Via: OncoMed REDWOOD CITY, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that five posters will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 14-18, 2018, in Chicago. Among the presentations will be preclinical data for OncoMed's novel anti-TIGIT (OMP-313M32) immuno-oncology program, which is currently in a Phase 1a single-agent clinical study. Preclinical data for OncoMed's differentiated clinical-stage GITRL-Fc (OMP-336B11) program will also be featured. In addition, preclinical immuno-oncology data for OncoMed's Wnt antagonist vantictumab (anti-FZD, OMP-18R5) in combination with immune checkpoint inhibitors will be presented. Via: Cision PR Newswire Plan helps accounts choose the right solutions to keep employees healthy and lower health care costs |
Archives
October 2023
|